Document:

<PAGE>

                                                                    Exhibit 10.1

                      AMENDMENT TO COLLABORATION AGREEMENT

     This Amendment to the Collaboration Agreement dated December 23, 1999
between Sankyo Pharma Inc. ("Sankyo"), a Delaware Corporation having its
principal place of business at Two Hilton Court, Parsippany, New Jersey 07054,
and Genzyme Corporation ("Genzyme"), a Massachusetts Corporation having its
place of business at 153 Second Avenue, Waltham, Massachusetts 02451 is made as
of the ___ day of January 2004 (the "Collaboration Agreement"), (the
"Amendment").

                                    RECITALS

     A. Sankyo and GelTex Pharmaceuticals, Inc. ("GelTex") heretofore entered
into a Collaboration Agreement dated December 23, 1999 (the "Agreement"), as
amended from time to time, for collaboration on the commercialization of
colesevelam (approved and marketed under the trade name WelChol(R)for the
reduction of elevated LDL cholesterol in patients with primary
hypercholesterolemia),

     B. [**] ("The `202 Application"),

     C. On April 1, 2003, GelTex merged with its parent corporation, Genzyme
Corporation and GelTex ceased to exist. Genzyme assumed all of GelTex's rights
and obligations under the Collaboration Agreement,

     D. Sankyo now desires, and Genzyme agrees to provide Sankyo with, a license
to the Product in an Expanded Field (as defined below) without extending the
term during which Genzyme is obligated to supply Drug Substance for purchase by
Sankyo, and Sankyo is obligated to purchase all of its requirements for Drug
Substance from Genzyme,

     E. Sankyo now desires to assign all rights to the `202 Application to
Genzyme, and

     F. All terms used in this Amendment shall have the same meaning as in the
Agreement, unless otherwise specifically stated herein.

     NOW, THEREFORE, in consideration of the foregoing and of the mutual
covenants herein contained, the parties hereto intending to be legally bound
hereby agree to the following amendments to the Agreement:

     1. Genzyme has agreed to provide Sankyo with certain rights to the Product
in an Expanded Field as set forth below. The parties acknowledge and agree that
the additional license rights granted herein within the Expanded Field shall be
limited and are not intended to expand any other licenses, intellectual property
rights or other rights and/or obligations of either party in connection with the
manufacture, use or sale of the Product in the Field set forth in the Agreement.
The parties have made their best efforts to ensure that the inclusion

[**] = Portions of this exhibit have been omitted pursuant to a confidential
       treatment request. An unredacted version of this exhibit has been filed
       separately with the Commission.

<PAGE>

of the Expanded Field in the license grant does not inadvertently expand any
other rights or obligations under the Agreement. To the extent any ambiguity
remains, Genzyme and Sankyo agree that unless a specific right or obligation is
expressly extended or expanded to include the Expanded Field in this Amendment,
all rights and obligations under the Agreement shall be limited to their scope
prior to this Amendment.

     2. Genzyme and Sankyo agree that upon execution of this Amendment, the
following modifications shall be made to the Agreement:

     2.1 The following new definitions shall be incorporated hereby in Article I
of the Agreement.

     "EXPANDED FIELD" shall mean the treatment or prevention of the following
indications irrespective of the mechanism of action to achieve the desired
therapeutic effect:

          i. Diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance, and
     Reduction of serum/plasma glucose levels;

          ii. Inflammatory Bowel Syndrome (IBS); and

          iii. Syndrome X (Dysmetabolic Syndrome)

     "EXPANDED GELTEX PATENT RIGHTS" shall mean the following GelTex pending
patent applications: "

          [**]

     2.2 The existing definitions in Article 1 of the terms referenced below
shall be deleted in their entirety and replaced in full with the definitions set
forth below:

     "GELTEX PATENT RIGHTS" shall mean the (i) subject matter related to the
development, manufacture, use, offer for sale or sale of Product in the Field
but not in the Expanded Field, claimed in or covered by the pending patent
application and issued patents recited in Exhibit B; and any continuations,
continuations-in-part, divisionals and foreign counterpart application thereof
and in any patents issuing on these applications, including reissues and
re-examinations; and (ii) Patent Rights claiming GelTex Inventions or Joint
Inventions (as such terms are defined in Section 7.1.1) to the extent such
Patent Rights relate to or are necessary or useful for the development,
manufacture, use, offer for sale or sale of Product and Sankyo agrees that such
Patent Rights should be included in GelTex Patent Rights.

     "GELTEX TECHNOLOGY" shall mean all present and, to the extent such
Technology is discovered, made or conceived during and in connection with this
Agreement, future Technology owned or controlled by, or licensed (with the right
to sublicense) to, GelTex or

[**] = Portions of this exhibit have been omitted pursuant to a confidential
       treatment request. An unredacted version of this exhibit has been filed
       separately with the Commission.

                                       2

<PAGE>

its Affiliates relating to or useful for the development, manufacture, use,
offer for sale or sale of Product in the Field and in the Expanded Field. GelTex
Technology shall not include technology licensed to GelTex under the Nittobo
License (as such term is defined below).

     "SANKYO PATENT RIGHTS" shall mean Patent Rights claiming Sankyo Inventions
or Joint Inventions (as such terms are defined in Section 7.1.1 hereof) to the
extent such Patent Rights relate to or are necessary or useful for the
development, manufacture, use, offer for sale or sale of Product in the Field
but not in the Expanded Field.

     "SANKYO TECHNOLOGY" shall mean Technology discovered, made or conceived
during and in connection with this Agreement, that is owned or controlled by, or
licensed (with the right to sublicense) to, Sankyo or its Affiliates relating to
or useful for the development, manufacture, use, offer for sale or sale of
Product in the Field but not in the Expanded Field. Sankyo Technology shall not
include marketing information developed or created by Sankyo or its Affiliates.

     2.3 Section 3.1.1 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

     3.1.1 PRODUCT. GelTex hereby grants to Sankyo: (i) the exclusive,
irrevocable (during the Term), right and license under the GelTex Patent Rights
and GelTex Technology and the Expanded GelTex Patent Rights to develop, make
(subject to the terms of Article 5), have made (subject to the terms of Article
5), have sold, use, import, offer for sale and sell Product for use in the
Territory in the Field or the Expanded Field, and to practice and have practiced
the methods licensed under the GelTex Patent Rights and Expanded GelTex Patent
Rights for such purpose; and (ii) the exclusive, irrevocable (during the Term)
right and license to use the registered trademark Cholestagel(R) in the
Territory in connection with the sale of Finished Product in the Field or the
Expanded Field. The exclusive license granted in Section 3.1.1(i) is subject to
licenses previously granted by GelTex to Chemie in order to permit Chemie to
manufacture Drug Substance for GelTex and GelTex's licenses. The license grants
under this Section 3.1.1 may be sublicensed by Sankyo following written notice
to GelTex.

     2.4 Section 5.1.1 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

     5.1.1 ENGAGEMENT OF CONTRACT MANAGEMENT. GelTex shall be responsible for
identifying and contracting with Manufacturers to produce Drug Substance, and
Sankyo shall source all of its requirements for Drug Substance from GelTex up to
and including December 30, 2014. Thereafter, all of Genzyme's obligations under
this Article 5, as amended, shall cease.

     2.5 Section 7.1.1 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

[**] = Portions of this exhibit have been omitted pursuant to a confidential
       treatment request. An unredacted version of this exhibit has been filed
       separately with the Commission.

                                       3

<PAGE>

     7.1.1 OWNERSHIP OF DISCOVERIES AND IMPROVEMENTS. All right, title and
interest in all writings, inventions, discoveries, improvements and other
Technology, whether or not patentable or copyrightable, and any patent
applications, patents or copyrights based thereon that are discovered, made or
conceived during and in connection with this Agreement (collectively, the
"INVENTIONS") solely by employees of GelTex or others acting on behalf of GelTex
("GELTEX INVENTIONS") shall be owned by GelTex by assignment. All right, title
and interest in all Inventions that are discovered, made or conceived during and
in connection with this Agreement solely by employees of Sankyo or others acting
on behalf of Sankyo ("SANKYO INVENTIONS") shall be owned by Sankyo by
assignment. All right, title and interest in all Inventions jointly invented by
employees of GelTex and Sankyo ("JOINT INVENTIONS") shall be jointly owned by
Sankyo and GelTex and assigned thereto by the respective employees. Each of
GelTex and Sankyo shall promptly disclose to the other Party the making,
conception or reduction to practice of Inventions by employees or others acting
on behalf of such Party or inventions licensed to the other Party hereunder.
Patent Rights and Technology covering GelTex Inventions and Joint Inventions
shall be automatically licensed to Sankyo in accordance with Section 3.1.1
hereof to the extent that Sankyo has determined to include such GelTex
Inventions and Joint Inventions in the definition of GelTex Patent Rights or
Expanded GelTex Patent Rights. Patent Rights and Technology covering Sankyo
Inventions and Joint Inventions shall be automatically licensed to GelTex in
accordance with Sections 3.2.1 and 3.2.2 hereof.

     2.6 Section 7.6 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

     7.6 ENFORCEMENT OF PATENT RIGHTS. GelTex and Sankyo shall promptly notify
the other in writing of any alleged or threatened infringement of GelTex Patent
Rights, Expanded GelTex Patent Rights or Sankyo Patent Rights of which it
becomes aware.

     2.7 Section 7.6.1 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

     7.6.1 FIRST RIGHT TO RESPOND. Sankyo shall have the first right, but not
obligation, to prosecute or prevent such infringement in the Field or the
Expanded Field in the Territory. Sankyo shall periodically inform GelTex of its
intended course of action and shall provide GelTex with the opportunity to
comment on significant actions or elements of Sankyo's strategy. Any action
taken by Sankyo pursuant to this Section 7.6.1 shall be at the sole cost and
expense of Sankyo, PROVIDED, HOWEVER, that GelTex shall have the right to
participate in any such action at its own expense. Sankyo shall have the right
to retain for itself all amounts recovered in connection with the infringement
whether by judgment, award, decree, or settlement, but all such amounts (reduced
by the reasonable and documented costs incurred by Sankyo in pursuing the
recovered amounts) shall be added to annual sales and subject to the same
royalty payment as Net Sales.

     2.8 Section 7.6.3 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

[**] = Portions of this exhibit have been omitted pursuant to a confidential
       treatment request. An unredacted version of this exhibit has been filed
       separately with the Commission.

                                       4

<PAGE>

         7.6.3 COOPERATION. If either Party has exercised its right to prosecute
or prevent the infringement of GelTex Patent Rights, Expanded GelTex Patent
Rights or Sankyo Patent Rights as described in Sections 7.6.1 and 7.6.2 hereof,
then the other Party shall provide reasonable and diligent cooperation with such
Party in all matters concerning any such infringement and shall make available
any relevant records, documents, or information if requested to do so.

     2.9 Section 13.1.1 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

     13.1.1 EXPIRATION. Unless terminated earlier pursuant to Section 13.2, this
Agreement shall continue in full force and effect until the expiration of the
last of any GelTex Patent Rights or Expanded GelTex Patent Rights in the
Territory.

     2.10 Section 13.1.2 of the Agreement shall be deleted in its entirety and
replaced in full with the following:

     13.1.2 EFFECT OF EXPIRATION. Expiration of the Agreement shall not relieve
the Parties of any obligation accruing prior to such expiration. Upon expiration
of this Agreement in connection with Product pursuant to Section 13.1.1 above:
(i) Sankyo shall have a paid-up, non-exclusive license, with right to
sublicense, under the GelTex Patent Rights, Expanded GelTex Patent Rights and
GelTex Technology to make, have made, use, offer for sale, sell and have sold
Product in the Territory for use in the Field or the Expanded Field; (ii) Sankyo
shall have a paid-up license and right to use the registered trademark
Cholestagel in the Territory in connection with the sale of Product for use in
the Field; and (iii) GelTex shall have a paid-up non-exclusive license under the
Sankyo Patent Rights and Sankyo Technology to make, have made, use, offer for
sale, sell and have sold Product in the Territory.

     3. Sankyo shall assign all rights to the `202 Application to Genzyme.
Genzyme shall prepare and file all appropriate assignment papers. All
continuations, continuations-in-part, divisionals and foreign counterpart
applications thereof and all patents issuing from the `202 Application,
including reissues and re-examinations thereof, shall be included in the
Expanded GelTex Patent Rights.

     4. GelTex hereby represents and warrants (i) that immediately prior to the
execution and delivery of this Amendment it possesses an exclusive right, title
and interest to the existing Expanded GelTex Patent Rights and the GelTex
Technology (except for licenses granted to Chemie); (ii) that the Expanded
GelTex Patent Rights and the GelTex Technology are, and during the Term will
remain free and clear of any lien or other encumbrance; and (iii) that GelTex
has the right to enter into the obligations set forth in this Amendment and to
grant the rights and licenses set forth in Article 3 of the Agreement.

     5. In all other regards, the Agreement shall remain unchanged and shall
continue in full force and effect, and all of its terms and conditions shall
apply hereto. Unless specifically

[**] = Portions of this exhibit have been omitted pursuant to a confidential
       treatment request. An unredacted version of this exhibit has been filed
       separately with the Commission.

                                       5

<PAGE>

agreed to by the parties in writing, the Field as set forth in the Agreement
shall not include the Expanded Field set forth in this Amendment.

     6. This Amendment may not be amended or modified nor may any provision
hereof or thereof be waived, except by a writing signed by both parties.

     IN WITNESS WHEREOF, and intending to be legally bound, the parties hereto
have caused this Agreement to be executed by their duly authorized
representatives.

SANKYO PHARMA INC.
By:
        ------------------------------------------------------------------------

Name:   John P. Gargiulo
        ------------------------------------------------------------------------

Title:  Vice President, Marketing and Commercial Operations
        ------------------------------------------------------------------------

GENZYME CORPORATION
By:
        ------------------------------------------------------------------------

Name:   Edmund Sybertz
        ------------------------------------------------------------------------

Title:  Senior Vice President and General Manager
        ------------------------------------------------------------------------

[**] = Portions of this exhibit have been omitted pursuant to a confidential
       treatment request. An unredacted version of this exhibit has been filed
       separately with the Commission.

                                       6QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
    

 
 

FIRST AMENDMENT TO CREDIT AGREEMENT (364-DAY)    
    

        This First Amendment to Credit Agreement (364-Day) (the "Amendment") dated as of April 8, 2004
by and among Alliance Data Systems Corporation (the "Borrower"), the Guarantor party hereto, the Banks party hereto, and Harris Trust and Savings Bank,
as Administrative Agent; 

W
I T N E S S E T H: 

        WHEREAS,
the Borrower, the Guarantors, the Banks, and the Administrative Agent have heretofore executed and delivered a Credit Agreement (364-Day) dated as of
April 10, 2003 (the "Credit Agreement"); and 

        WHEREAS,
the Borrower, the Guarantors, the Banks and the Agent desire to amend the Credit Agreement to extend the Maturity Date and to make certain other amendments to the Credit
Agreement as set forth herein; 

        NOW,
THEREFORE, for good and valuable consideration the receipt of which is hereby acknowledged, the Borrower, the Banks and the Administrative Agent hereby agree as follows: 

        1.     The
definition of "Maturity Date" contained in Section 1.1 of the Credit Agreement is hereby amended in its
entirety to read as follows: 

        "Maturity Date" means April 7, 2005. 

        2.     The
Borrower has requested that from and after the Effective Time the Commitments of the Banks be reallocated among the Banks;  provided that the aggregate amount of the Commitments do not exceed
$150,000,000. Accordingly, the Commitments of the Banks set forth on
Schedule I to the Credit Agreement are hereby amended in their entirety and as so amended shall be as set forth on Schedule I to this Amendment. 

        3.     This
Amendment shall become effective as of the opening of business on April 8, 2004 (the "Effective Time") subject
to the conditions precedent that on or before such date: 

        (a)   the
Administrative Agent shall have received counterparts hereof executed by the Borrower, Guarantor and each Bank; 

        (b)   the
Administrative Agent shall have received certified copies of resolutions of the Board of Directors of the Borrower and Guarantor authorizing the execution and
delivery of this Amendment, indicating the authorized signers of this Amendment and the specimen signatures of such signers; and 

        (c)   an
opinion of counsel to the Borrower and Guarantor in form reasonably acceptable to the Administrative Agent and covering such matters relating to the transactions
contemplated hereby as the Administrative Agent or the Required Banks may reasonably request. 

 

        4.1.  To
induce the Administrative Agent and the Banks to enter into this Amendment, the Borrower represents and warrants to the Administrative Agent and the Banks that:
(a) the representations and warranties contained in the Credit Agreement are true and correct in all material respects as of the date hereof with the same effect as though made on the date
hereof (it being understood and agreed that any representation or warranty which by its terms is made as of a specified date shall be required to be true and correct in all material respects only as
of such specified date); (b) no Default or Event of Default exists; (c) this Amendment has been duly authorized by all necessary corporate proceedings and duly executed and delivered by
the Borrower and the Credit Agreement, as amended by this Amendment, is the legal, valid and binding obligations of the Borrower, enforceable against the Borrower in accordance with its terms, except
as enforceability may be limited by bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditors' rights or by general principles of equity; and
(d) no consent, approval, authorization, order, registration or qualification with any governmental authority is required for, and in the absence of which would adversely effect, the legal and
valid execution and delivery or performance by the Borrower of this Amendment or the performance by the Borrower of the Credit Agreement, as amended by this Amendment. 

        4.2.  This
Amendment may be executed in any number of counterparts and by the different parties on separate counterparts and each such counterpart shall be deemed to be an
original, but all such counterparts shall together constitute but one and the same Amendment. 

        4.3.  Except
as specifically provided above, the Credit Agreement shall remain in full force and effect and is hereby ratified and confirmed in all respects. The execution,
delivery, and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a waiver of any right, power, or remedy of the Administrative Agent or any Bank under the
Credit Agreement or any Note, nor constitute a waiver or modification of any provision of any of the Credit Agreement or any Note. 

        4.4.  This
Amendment and the rights and obligations of the parties hereunder shall be construed in accordance with and be governed by the law of the State of Illinois. 

2

  

        IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written. 

	

 	
 	

ALLIANCE DATA SYSTEMS CORPORATION, as Borrower
	

 	
 	

By:	

/s/  ROBERT P. ARMIAK    

Robert P. Armiak
 Name: Robert P. Armiak

Title: Senior Vice President & Treasurer
	

 	
 	

ADS ALLIANCE DATA SYSTEMS, INC., as a Guarantor
	

 	
 	

By:	

/s/  ROBERT P. ARMIAK      
 Name: Robert P. Armiak

Title: Senior Vice President & Treasurer
	

 	
 	

HARRIS TRUST AND SAVINGS BANK, individually, as Letter of Credit Issuer and as Administrative Agent
	

 	
 	

By:	

/s/  PETER F. STACK      
 Name: Peter F. Stack

Title: Vice President
	

 	
 	

SUNTRUST BANK
	

 	
 	

By:	

/s/  BRIAN K. PETERS      
 Name: Brian K. Peters

Title: Managing Director
	

 	
 	

BANK ONE, N.A. (Main Office Chicago)
	

 	
 	

By:	

/s/  MARK WASDEN      
 Name: Mark Wasden

Title: Director
	

 	
 	

WACHOVIA BANK, N.A.
	

 	
 	

By:	

/s/  STEVEN L. HIPSMAN      
 Name: Steven L. Hipsman

Title: Director
	 	 	 	 

S-1

 

	

 	
 	

JPMORGAN CHASE BANK
	

 	
 	

By:	

/s/  MICHAEL J. LISTER      
 Name: Michael J. Lister

Title: Vice President
	

 	
 	

HUNTINGTON NATIONAL BANK
	

 	
 	

By:	

/s/  LYNN A. KARR      
 Name: Lynn A. Karr

Title: Senior Vice President
	

 	
 	

CREDIT SUISSE FIRST BOSTON, Acting Through Its Cayman Islands Branch
	

 	
 	

By:	

/s/  PETER CHAUVIN      
 Name: Peter Chauvin

Title: Vice President
	

 	
 	

By:	

/s/  ALAIN DAOUST      
 Name: Alain Daoust

Title: Director
	

 	
 	

U.S. BANK N.A.
	

 	
 	

By:	

/s/  JOSEPH L. SOOTER, JR.      
 Name: Joseph L. Sooter, Jr.

Title: Vice President
	

 	
 	

UNION BANK OF CALIFORNIA, N.A.
	

 	
 	

By:	

/s/  CLIFFORD F. CHO      
 Name: Clifford F. Cho

Title: Assistant Vice President
	

 	
 	

FIFTH THIRD BANK (Central Ohio)
	

 	
 	

By:	

/s/  KRISTIE L. NICOLOSI      
 Name: Kristie L. Nicolosi

Title: Assistant Vice President
	

 	
 	

BARCLAYS BANK PLC
	

 	
 	

By:	

/s/  ALISON MCGUIGAN      
 Name: Alison McGuigan

Title: Associate Director

S-2

 
 

Schedule I    
    

	Bank
 
	 	Commitment

	Harris Trust and Savings Bank	 	$	15,000,000
	

SunTrust Bank	
 	
$	

20,000,000
	

Bank One, N.A. (Main Office Chicago)	
 	
$	

10,000,000
	

Wachovia Bank, N.A.	
 	
$	

15,000,000
	

JPMorgan Chase Bank	
 	
$	

10,000,000
	

Huntington National Bank	
 	
$	

15,000,000
	

Barclays Bank PLC	
 	
$	

20,000,000
	

Fifth Third Bank	
 	
$	

15,000,000
	

Credit Suisse First Boston Cayman Islands Branch	
 	
$	

10,000,000
	

Union Bank of California, N.A.	
 	
$	

10,000,000
	

U.S. Bank N.A.	
 	
$	

10,000,000

QuickLinks

Exhibit 10.1

FIRST AMENDMENT TO CREDIT AGREEMENT (364-DAY)

Schedule I

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]